Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.59 |
| ▸ | TUBB | P07437 | 4/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.59 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.59 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.59 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.59 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.59 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.59 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.59 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.59 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyphenstatin SCHEMBL30910835 | 0.89 | KDM4E (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Hydroxyphenstatin SCHEMBL13197632 | 0.89 | KDM4E (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL19003423 | 0.89 | HDAC1 (0.72) | HDAC1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8686068 | 0.87 | HDAC1 (0.69) | HDAC1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL26441450 | 0.86 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL353184 | 0.86 | SLC22A6 (0.72) | HDAC1KDM4EMAPTMAPK1HSD17B10 | |
| SCHEMBL29670589 | 0.86 | SLC22A6 (0.72) | HDAC1KDM4EMAPTMAPK1HSD17B10 | |
| SCHEMBL4821487 | 0.86 | MAPT (0.63) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL21845093 | 0.83 | TUBB4A (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL26441495 | 0.82 | TUBB4A (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639325-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639325-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11180438-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210171429-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200087236-A9 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2017106861-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639325-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | HDAC1, HDAC10, HDAC6 | HDAC1 1/4885TUBB4A 599/4885TUBB 605/4885 |
| US-11180438-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | HDAC1, HDAC10, HDAC6 | HDAC1 1/4885TUBB4A 599/4885TUBB 605/4885 |
| US-20200087236-A9 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | HDAC1, HDAC10, HDAC6 | HDAC1 1/4885TUBB4A 599/4885TUBB 605/4885 |
| US-20210171429-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | HDAC1, HDAC10, HDAC6 | HDAC1 1/4885TUBB4A 599/4885TUBB 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.